Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021

Video

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork® about the benefits of a conference like the American Association for Cancer Research (AACR) Annual Meeting 2021, and how the collaborative network of thought leaders presents ample opportunity to move the field forward.

Transcription:

What I think the AACR Annual Meeting does is bring together experts from a multitude of fields across the globe to really aim towards one specific goal of understanding cancer and reducing the burden of cancer worldwide. I think that’s a really unique opportunity because these different presentations, mine as well as other posters, other sessions, really afford the opportunity to forge connections and collaborations that you may not have had within your inner network. [Connecting] folks of different expertise may yield just fantastic team science and translational work to answer important questions like these in early-onset colorectal cancer. I’m most excited for that, in addition to presenting these findings, the provocative discussion that will be held both with these results and how we as a field can move forward to really make that precision medicine impact for individual patients overall. From basic science to population science, you’re really bringing together a [group] of experts to really build upon what we already know and go in ways that we may not have thought of individually.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Related Content